Efaproxiral

Efaproxiral is a haemoglobin (Hb) synthetic allosteric modifier, decreases Hb-oxygen (O2) binding affinity and enhances oxygenation of hypoxic tumours during radiation therapy [1].

Product Specifications

CAS Number

[131179-95-8]

Product Name Alternative

RSR13

UNSPSC

12352005

Hazard Statement

H302

Target

Reactive Oxygen Species (ROS)

Type

Reference compound

Related Pathways

Immunology/Inflammation; Metabolic Enzyme/Protease; NF-κB

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/Efaproxiral.html

Concentration

10mM

Purity

99.94

Solubility

DMSO : ≥ 150 mg/mL

Smiles

CC(C)(OC1=CC=C(CC(NC2=CC(C)=CC(C)=C2)=O)C=C1)C(O)=O

Molecular Formula

C20H23NO4

Molecular Weight

341.40

Precautions

H302

References & Citations

[1]Stea B, et al. Efaproxiral red blood cell concentration predicts efficacy in patients with brain metastases. Br J Cancer. 2006 Jun 19;94 (12) :1777-1784.|[2]Abraham DJ, et al. Allosteric modifiers of hemoglobin: 2-[4-[[ (3,5-disubstituted anilino) carbonyl]methyl]phenoxy]-2-methylpropionic acid derivatives that lower the oxygen affinity of hemoglobin in red cell suspensions, in whole blood, and in vivo in rats. Biochemistry. 1992 Sep 29;31 (38) :9141-9.|[3]Hou H, et al. The effects of Efaproxyn (efaproxiral) on subcutaneous RIF-1 tumor oxygenation and enhancement of radiotherapy-mediated inhibition of tumor growth in mice. Radiat Res. 2007 Aug;168 (2) :218-25.|[4]Hou H, et al. Increased oxygenation of intracranial tumors by efaproxyn (efaproxiral), an allosteric hemoglobin modifier: In vivo EPR oximetry study. Int J Radiat Oncol Biol Phys. 2005 Apr 1;61 (5) :1503-9.